# Alivexis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alivexis

- Industry: Pharmaceuticals
- Headquarters: Tokyo, Japan
- Website: www.alivexis.com
- Total disclosed funding: $62M
- Latest round: Series D (Jan 7, 2025)
- Investors on record: 17

## About

Alivexis, Inc. is a Tokyo-based company focused on advanced data analytics and software solutions that enhance decision-making across various industries, including finance and healthcare.Founded in 2016 in Tokyo, Japan, Alivexis, Inc. specializes in data analytics and software development aimed at enhancing decision-making processes. The company has engaged in four significant deals, with its most recent funding round being a Series C raised on March 4, 2022, garnering JPY 2.3 billion from investors such as SBI Holdings and Heights Capital Management. The firm currently holds a valuation of JPY 15.6 billion based on total funds raised of JPY 2.3 billion during its latest round.Alivexis, Inc. specializes in advanced data analytics and software solutions aimed at enhancing decision-making processes within various industries. The company's core offerings include proprietary analytical tools designed to process and visualize complex datasets, enabling clients to derive actionable insights. These products cater to a diverse clientele, including financial institutions, healthcare organizations, and technology firms, all seeking to improve operational efficiency and strategic planning. Modulus Discovery's services are particularly valuable in the realms of risk assessment, market analysis, and predictive modeling, addressing critical needs for accurate forecasting and data-driven decision-making. The company primarily serves markets in North America, Europe, and parts of Asia, ensuring a broad geographical reach that aligns with the global demand for sophisticated data solutions.Modulus Discovery operates on a subscription-based revenue model, offering clients access to its suite of analytical tools and services through tiered pricing plans. Clients engage with the company under contractual agreements that may include annual subscriptions or project-based fees, depending on the scope of services required. The flagship products are designed to facilitate both B2B and direct-to-consumer transactions, allowing organizations to leverage data insights for competitive advantages. Revenue generation is supported by partnerships with key industry players, further enhancing the company's market presence and service delivery capabilities. Through these structured engagements, Modulus Discovery establishes a consistent revenue stream, reflecting its commitment to delivering high-value solutions to its diverse client base.In March 2022, Modulus Discovery raised JPY 2.3 billion in Series C funding, which will be utilized for research and development of its proprietary computational drug discovery platform and globally networked operational model. The company plans to accelerate its existing pipeline of over 10 R&D programs. Additionally, Modulus Discovery is targeting new geographic markets for expansion, which will be detailed in upcoming product releases. These initiatives are expected to enhance the company's capabilities and market reach.

## Funding rounds

- Series D, Jan 7, 2025, $5.1M — DBJ Capital, Fast Track Initiative, JIC Venture Growth Investments
- Series C, Mar 4, 2022, $20M — SBI Holdings, JAFCO Group, Heights Capital Management, Fast Track Initiative, Keio Innovation Initiative, UTokyo Innovation Platform, Green Co-Invest Investment
- Series B, May 13, 2020, $25M — Dai-ichi Life Insurance, JAFCO Group, Mobile Internet Capital, SMBC Venture Capital, Mizuho Capital, SBI Investment, Fast Track Initiative, Keio Innovation Initiative, UTokyo Innovation Platform, Medifuture, Essential Pharma
- Series A, Aug 9, 2018, $7.2M — DBJ Capital, Fast Track Initiative, PeptiDream Inc.
- Series A, Aug 23, 2017, $3.6M — DBJ Capital, Fast Track Initiative

## Investors

- DBJ Capital (https://capitalatlas.ai/funds/dbj-capital) — Series A, Series D
- Fast Track Initiative (https://capitalatlas.ai/funds/fast-track-initiative) — Series A, Series B, Series C, Series D
- PeptiDream Inc. — Series A
- Dai-ichi Life Insurance — Series B
- JAFCO Group (https://capitalatlas.ai/funds/jafco-group) — Series B, Series C
- Mobile Internet Capital (https://capitalatlas.ai/funds/mobile-internet-capital) — Series B
- SMBC Venture Capital (https://capitalatlas.ai/funds/smbc-venture-capital) — Series B
- Mizuho Capital (https://capitalatlas.ai/funds/mizuho-capital) — Series B
- SBI Investment (https://capitalatlas.ai/funds/sbi-investment) — Series B
- Keio Innovation Initiative (https://capitalatlas.ai/funds/keio-innovation-initiative) — Series B, Series C
- UTokyo Innovation Platform (https://capitalatlas.ai/funds/utokyo-innovation-platform) — Series B, Series C
- Medifuture — Series B
- Essential Pharma — Series B
- SBI Holdings — Series C
- Heights Capital Management (https://capitalatlas.ai/funds/heights-capital-management) — Series C
- Green Co-Invest Investment — Series C
- JIC Venture Growth Investments (https://capitalatlas.ai/funds/jic-venture-growth-investments) — Series D